Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Instagram Outage Disrupts Thousands of U.S. Users 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
BASEL, Switzerland and CAMBRIDGE, Mass., Nov. 08, 2016 -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines, today announced Rodger Novak, M.D., Chief Executive Officer and Founder of CRISPR Therapeutics, will present at the Stifel 2016 Healthcare Conference on Tuesday, November 15, 2016 at the Lotte New York Palace Hotel, New York.
Event: Stifel 2016 Healthcare Conference
Date: Tuesday, November 15, 2016
Time: 11:45 AM ET
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors & Media section of the Company's website at www.crisprtx.com.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform.
MEDIA CONTACTS: Jennifer Paganelli W2O Group for CRISPR 347-658-8290 [email protected] INVESTOR CONTACT: Chris Brinzey Westwicke Partners for CRISPR 339-970-2843 [email protected]
